List of Excipients in Branded Drug RUXIENCE

Ruxience Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Ruxience is Pfizer’s rituximab-pvvr biosimilar, supplied as an intravenous concentrate containing rituximab, sodium chloride, sodium citrate dihydrate, polysorbate 80, and Water for Injection. Its excipient strategy is conservative: it reproduces the established rituximab liquid formulation platform rather than pursuing a differentiated delivery system. Commercial opportunities therefore sit primarily in high-quality excipient supply, formulation manufacturing, container-closure systems, stability services, and future subcutaneous or ready-to-administer products.

What is Ruxience and which excipients does it contain?

Ruxience, or rituximab-pvvr, is a monoclonal antibody biosimilar to Rituxan, also known as MabThera outside the United States. The FDA approved Ruxience on July 23, 2020, under the 351(k) biosimilar pathway.[1]

The product is supplied in two single-dose vial strengths:

Product	Fill volume	Rituximab concentration	Primary use
Ruxience 100 mg/10 mL	10 mL	10 mg/mL	Weight- or body-surface-area-based dosing
Ruxience 500 mg/50 mL	50 mL	10 mg/mL	Higher-dose administration

The labeled formulation contains the following excipients per milliliter:[2]

Excipient	Approximate concentration	Functional role
Sodium chloride	9.0 mg/mL	Tonicity adjustment
Sodium citrate dihydrate	7.35 mg/mL	Buffering and pH control
Polysorbate 80	0.23 mg/mL	Prevention of protein adsorption and aggregation
Water for Injection	q.s.	Solvent

The finished formulation has a target pH of approximately 6.0. Ruxience is diluted before intravenous infusion in an appropriate infusion solution, typically 0.9% sodium chloride or 5% dextrose, according to the prescribing information.[2]

Why did Pfizer use a conventional excipient system for Ruxience?

The formulation reduces biosimilarity risk by using excipients with established use in rituximab products and injectable monoclonal antibodies. A biosimilar sponsor must demonstrate that differences from the reference product do not produce clinically meaningful differences in safety, purity, or potency.[3]

A conventional formulation supports that objective in four ways:

1. It uses pharmacopeial excipients with extensive parenteral history.
2. It avoids novel stabilizers that could introduce immunogenicity or safety concerns.
3. It supports comparability across analytical, preclinical, and clinical development stages.
4. It reduces regulatory questions relating to new excipient toxicology or administration behavior.

Ruxience’s excipient system is therefore optimized for regulatory acceptability and manufacturing reproducibility rather than product differentiation.

What does each Ruxience excipient do?

Polysorbate 80

Polysorbate 80 is the principal protein-stabilizing excipient. It limits adsorption of rituximab to vial, syringe, tubing, and infusion-bag surfaces. It also reduces interfacial stress during handling, dilution, and infusion.

The main commercial risks involve:

• Peroxide and aldehyde impurities
• Batch-to-batch variability
• Hydrolytic degradation
• Oxidative stress on the antibody
• Subvisible particles
• Lot-to-lot differences in fatty-acid distribution

For monoclonal antibody manufacturers, polysorbate 80 is a high-value control point even though its unit cost is modest. Supplier qualification, incoming testing, storage conditions, and compatibility with the selected container-closure system can affect product stability.

Sodium citrate dihydrate

Sodium citrate dihydrate provides buffering capacity and helps maintain the target formulation pH. Buffer selection can influence aggregation, charge variants, viscosity, degradation pathways, and compatibility with the reference product.

Citrate is commercially attractive because it is widely available and has a mature regulatory profile. The opportunity is not a novel citrate molecule. It is control of grade, purity, bioburden, endotoxin, and supply continuity.

Sodium chloride

Sodium chloride adjusts tonicity and supports intravenous compatibility. Its role is technically simple but operationally important. Injectable-grade sodium chloride must meet strict requirements for particulate matter, endotoxin, microbial quality, and elemental impurities.

Water for Injection

Water for Injection is the principal solvent and must meet compendial and manufacturing-system requirements. Commercial opportunities include purified-water generation, sterile compounding, validated holding systems, and container-closure integrity rather than proprietary excipient chemistry.

What formulation patents protect Ruxience?

Ruxience does not appear to rely on a publicly identified, stand-alone excipient patent estate that differentiates it from other rituximab biosimilars. The core formulation uses standard excipients and does not publicly present a novel delivery technology.

The relevant intellectual-property layers are more likely to include:

IP layer	Relevance to Ruxience
Rituximab composition-of-matter patents	Historically important for the reference product; generally mature or expired in major markets
Reference-product formulation patents	May cover concentration, stabilizer systems, pH, or liquid storage
Process patents	May cover cell culture, purification, viral clearance, or manufacturing controls
Analytical and comparability know-how	Important operationally but not always visible in published patent claims
Container-closure and device patents	Relevant to vials, syringes, infusion systems, or future subcutaneous delivery
Manufacturing trade secrets	Likely important for yield, aggregate control, and product quality

A public patent review should distinguish between patents that literally claim a formulation containing rituximab and patents that claim broader antibody formulations. Broad antibody-formulation claims can be commercially relevant without naming Ruxience.

Ruxience is a biologic, so its regulatory exclusivity is not managed through the FDA Orange Book. Biologic patents and biosimilar exclusivity are assessed through the Purple Book and related patent-dispute mechanisms.[4]

When does Ruxience lose exclusivity?

Ruxience was approved under the U.S. biosimilar pathway and received the statutory biosimilar exclusivity period applicable to the first biosimilar approved for a reference product, if the statutory conditions were met. The key commercial question is not a conventional small-molecule generic expiration date. It is the combination of reference-product exclusivity, patent settlements, manufacturing capability, and payer access.

Ruxience’s principal regulatory milestones are:

Milestone	Date
FDA approval	July 23, 2020
U.S. commercial launch	2021
Reference product	Rituxan
FDA pathway	351(k) biosimilar
Orange Book listing	Not applicable
Purple Book relevance	Yes
Product type	Intravenous monoclonal antibody

Ruxience does not have an Orange Book patent listing because the Orange Book primarily covers approved drug products, including small molecules, rather than biologic reference products and biosimilars. Ruxience’s patent position must be evaluated through biologic patent records, the Purple Book, FDA approval materials, and litigation databases.

What is the FDA regulatory status of Ruxience?

Ruxience is FDA-approved for the same principal disease areas as Rituxan, subject to the approved label. These include:

• Non-Hodgkin’s lymphoma
• Chronic lymphocytic leukemia
• Rheumatoid arthritis
• Granulomatosis with polyangiitis
• Microscopic polyangiitis
• Pemphigus vulgaris

The FDA label includes boxed warnings and infusion-related safety requirements. Patients receive premedication and monitoring during administration. These requirements affect commercial formulation opportunities because any new excipient, concentration, container, or administration format must preserve infusion compatibility and product safety.[2]

A formulation change could require a comparability package under biologics regulations. A major change in excipient concentration, pH, concentration, or container may trigger additional stability, analytical, and potentially clinical work.

How does Ruxience compare with Truxima and Riabni?

Ruxience competes with other U.S.-approved rituximab biosimilars, including Truxima and Riabni. All three products compete primarily on price, supply reliability, contracting, provider preference, and payer policy.

Product	Sponsor	Active ingredient	Administration	Strategic formulation position
Rituxan	Genentech/Biogen in the United States	Rituximab	Intravenous	Reference product
Truxima	Celltrion	Rituximab-abbs	Intravenous	Biosimilar
Ruxience	Pfizer	Rituximab-pvvr	Intravenous	Biosimilar
Riabni	Amgen	Rituximab-arrx	Intravenous	Biosimilar

The excipient systems are broadly similar because the products must deliver a highly comparable antibody while meeting intravenous safety and stability requirements. The competitive advantage is therefore less likely to come from a unique excipient and more likely to come from:

• Lower cost of goods
• Reliable polysorbate and buffer supply
• Higher manufacturing yield
• Reduced aggregate formation
• Longer validated shelf life
• Better vial utilization
• Fewer preparation losses
• Payer and hospital contracting

What commercial opportunities exist in Ruxience excipients?

Can excipient suppliers sell into the Ruxience supply chain?

Yes. The strongest opportunities are in qualified, pharmaceutical-grade inputs and technical services rather than unprotected commodity chemicals.

Polysorbate 80 supply

Polysorbate 80 is the most technically sensitive excipient in the formulation. Suppliers with low-peroxide, low-impurity, consistent pharmaceutical-grade material can compete on:

• Oxidative stability
• Fatty-acid profile
• Trace-metal control
• Low particulate burden
• Global regulatory documentation
• Dual-source qualification

Because polysorbate degradation can affect antibody quality, suppliers that provide impurity profiling and stability support have a stronger commercial position than suppliers selling undifferentiated material.

Buffer and tonicity materials

Sodium citrate dihydrate and sodium chloride are lower-margin products. Suppliers can create value through:

• Sterile or low-bioburden grades
• Regional inventory
• Compendial compliance
• Extractables and leachables documentation
• Supply agreements covering multiple manufacturing sites
• Validated change-control procedures

Water and sterile manufacturing infrastructure

Water for Injection is not normally a separately branded product opportunity for Ruxience. The opportunity lies in manufacturing infrastructure, including sterile compounding, water-system qualification, microbial control, and process validation.

Are formulation services a commercial opportunity?

Yes. Contract development and manufacturing organizations can support Ruxience-like products through:

• Liquid monoclonal antibody formulation development
• Polysorbate optimization
• Freeze-thaw and agitation studies
• Vial and stopper compatibility
• Infusion-bag compatibility
• Subvisible-particle testing
• Forced-degradation studies
• Sterile filtration and aseptic filling
• Container-closure integrity testing

The most valuable work is likely to involve process robustness and comparability rather than discovery of a new excipient.

What manufacturing and IP barriers affect Ruxience opportunities?

Ruxience’s excipients are generally not the principal manufacturing barrier. The larger barriers are biologic-drug production and quality control.

Key barriers include:

1. Cell-line and upstream-process performance.
2. Protein A and downstream purification capacity.
3. Control of aggregates and charge variants.
4. Viral clearance validation.
5. Sterile filtration and aseptic filling.
6. Long-term stability data.
7. Demonstration of analytical similarity.
8. Regulatory acceptance of manufacturing changes.
9. Supply-chain continuity for polysorbate 80.
10. Hospital and payer adoption.

Manufacturing know-how may be more defensible than excipient selection. A competitor could use the same sodium chloride, citrate, and polysorbate 80 ingredients but still fail to reproduce product quality because of differences in cell culture, purification, concentration, filtration, or filling.

What method-of-use patents and biosimilar litigation affect Ruxience?

Rituximab has historically been associated with patent disputes involving the reference product’s composition, formulations, methods of treatment, and manufacturing processes. For a biosimilar, method-of-use patents can affect commercial launch even when the core antibody patent has expired.

The main legal risks include:

• Patents covering dosing schedules
• Indications not carved out of the biosimilar label
• Combination-treatment methods
• Subcutaneous delivery systems
• Manufacturing and purification claims
• Patent settlements that delay or condition launch

Ruxience is not a small-molecule product subject to a conventional Paragraph IV filing. Biosimilar patent disputes arise under the Biologics Price Competition and Innovation Act, including the patent-exchange process commonly called the "patent dance." A biosimilar applicant may also face litigation under 35 U.S.C. § 271(e)(2) or other patent-infringement theories.[4]

No public evidence indicates that a Ruxience excipient patent dispute has become a primary market constraint. The commercial focus has been biosimilar launch timing, reference-product patents, manufacturing claims, and contracting.

Does Ruxience have a subcutaneous formulation opportunity?

The largest potential formulation opportunity is a subcutaneous rituximab product, not a redesigned intravenous excipient system. Subcutaneous administration generally requires a substantially higher antibody concentration and may use a delivery-enabling excipient such as recombinant human hyaluronidase in the reference product’s commercial platform.

A subcutaneous Ruxience product could offer:

• Shorter administration time
• Reduced infusion-center utilization
• Lower nursing-resource requirements
• Greater convenience for maintenance therapy
• Potential differentiation from intravenous biosimilars

The barriers are significant. A subcutaneous product would require a new formulation and delivery system, new device or administration configuration, additional comparability work, local-tolerance assessment, and potentially clinical bridging. It would also encounter patents covering high-concentration formulations, hyaluronidase combinations, devices, and administration methods.

What revenue exposure does Ruxience create for Pfizer?

Pfizer does not generally disclose Ruxience revenue as a separately reported product line in its principal public financial statements. Revenue exposure is therefore best assessed through the size of the rituximab market, the number of biosimilar competitors, net price erosion, and Pfizer’s share of hospital and payer contracts.

Ruxience’s commercial economics are affected by:

• U.S. and European biosimilar discounts
• Payer preference for lower-net-cost products
• Hospital group purchasing contracts
• Oncology clinic acquisition and administration margins
• Manufacturing utilization
• Competitive supply shortages
• Indication-specific demand
• Intravenous infusion capacity

For excipient suppliers, the addressable opportunity is smaller than the biologic’s sales value. It is recurring and operationally important, but the main value pool remains antibody manufacturing, fill-finish, distribution, and market access.

How strong is the Ruxience patent estate?

Ruxience has a moderate product-protection position but not because of a differentiated excipient patent portfolio. Its commercial durability is based on:

• FDA biosimilar approval
• Pfizer’s manufacturing and regulatory infrastructure
• Established clinical use of rituximab
• Hospital and payer contracting
• Supply reliability
• Potential protection around manufacturing know-how

Its excipient patent strength is limited. Sodium chloride, sodium citrate, polysorbate 80, and Water for Injection are established materials. Any enforceable protection would likely depend on a narrow combination, concentration range, process condition, container system, or use claim rather than the individual excipients.

Key Takeaways

• Ruxience contains rituximab-pvvr, sodium chloride, sodium citrate dihydrate, polysorbate 80, and Water for Injection.
• The formulation is conventional and designed to minimize biosimilarity and regulatory risk.
• Polysorbate 80 is the most technically sensitive excipient because degradation can affect protein stability and particle formation.
• Ruxience has no Orange Book patent listing; biologic patent analysis belongs in the Purple Book and BPCIA framework.
• The principal competitive risks are other rituximab biosimilars, payer contracting, manufacturing scale, and patent settlements.
• The strongest excipient opportunities are qualified polysorbate 80, formulation services, sterile filling, container-closure systems, and stability testing.
• A future subcutaneous or high-concentration Ruxience product would offer greater commercial differentiation but face higher regulatory and patent barriers.
• No publicly established Ruxience-specific excipient patent estate appears to be the primary commercial protection mechanism.

FAQs

Does Ruxience contain polysorbate 80?

Yes. Ruxience contains approximately 0.23 mg/mL of polysorbate 80 as a protein-stabilizing excipient.

Is Ruxience a generic drug or a biosimilar?

Ruxience is a biosimilar, not a conventional generic. It was approved under the FDA’s 351(k) biologics pathway.

Does Ruxience use the same excipients as Rituxan?

Ruxience uses a conventional rituximab excipient system containing sodium chloride, sodium citrate dihydrate, polysorbate 80, and Water for Injection. Exact formulation equivalence must be assessed against the approved product labels and regulatory records.

Are Ruxience excipients protected by patents?

The individual excipients are established materials and are not, by themselves, a meaningful exclusivity barrier. Any relevant protection would more likely involve a specific formulation, process, container, delivery system, or method of use.

Could Ruxience be converted to a ready-to-use infusion product?

A ready-to-use presentation could reduce pharmacy preparation work, but it would require validated stability after dilution, container compatibility, microbial-control measures, transport validation, and regulatory approval for the changed presentation.

References

1. U.S. Food and Drug Administration. (2020). FDA approves rituximab biosimilar for non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and other indications. https://www.fda.gov
2. Pfizer Inc. (2023). Ruxience (rituximab-pvvr) injection prescribing information. https://labeling.pfizer.com
3. U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry. https://www.fda.gov
4. U.S. Food and Drug Administration. (2023). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.